Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingB-Raf and the inhibitors: from bench to bedsideSystemic treatments for metastatic cutaneous melanomaRelief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomasCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsGenomic diversity of colorectal cancer: Changing landscape and emerging targetsResistant mechanisms to BRAF inhibitors in melanomaMeningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibDabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersPractical aspects of NGS-based pathways analysis for personalized cancer science and medicineCutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the LiteratureMelanoma and the Unfolded Protein ResponseCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapySomatic DNA mutation analysis in targeted therapy of solid tumoursChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyVemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic MelanomaNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaNew therapeutic strategies for BRAF mutant colorectal cancersMedical management of malignant melanomaLong-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsMelanoma: oncogenic drivers and the immune systemTreatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine TrialsRecent advances in the treatment of melanoma with BRAF and MEK inhibitorsNew developments in the management of advanced melanoma - role of pembrolizumabTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Statistical Methods for Establishing Personalized Treatment Rules in OncologyManaging Side Effects of Vemurafenib Therapy for Advanced MelanomaImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyAdoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergyIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaPredictive biomarkers in precision medicine and drug development against lung cancerUniverses collide: combining immunotherapy with targeted therapy for cancerEmerging targeted therapies for melanoma treatment (review)Melanoma-associated leukoderma - immunology in black and white?Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerTumour heterogeneity and the evolution of polyclonal drug resistance
P2860
Q21133611-BBA48785-694A-4E88-B609-6F61CA0E2671Q21198860-BF2C0B22-A7C4-433B-BC25-B8FF3EDDDBBAQ24194804-6C4DAFCC-2589-4F9D-8A7A-21671DCA8A6BQ24303940-952437F5-0B2E-4FC9-A790-1AB3B774D656Q24632064-BBEEE082-4C9F-484E-8310-85B262A548E3Q26739052-1C95E4B8-0CEE-4F52-AFA1-4DFE1DBC641FQ26739717-E98C4DA6-53D2-4075-911B-0B316C77DECCQ26741529-CA140088-AA53-42B5-8B1F-9CABE66F0ACEQ26744335-2C7367DF-0235-4276-BAFB-6B147CE89F87Q26745933-781516F2-7B19-485C-822F-B6AA036B7773Q26747247-69CC67B9-7589-4D86-A952-0890E6C52689Q26747403-5EEC59E7-CCB4-494C-9512-FCB7F07DA2FDQ26748603-D107E9B9-B2AB-40DA-B8E7-505A1D4FB36DQ26752774-0D170548-D892-4767-B992-2C73446EE631Q26765426-F0EDAA8A-26C2-4F89-930B-1044BC84B198Q26769870-2EB2EAAA-BC5F-4BAD-B7AF-1979D69D2F35Q26770324-DA881F7F-8E23-4D20-99FC-0C87109420E0Q26770492-216CE509-1AA9-4160-B995-27B3CC9D6F98Q26771192-22A5B3AE-550F-47F4-ADD6-A097140E7306Q26771941-14810BAB-FE0E-461A-B2DE-2B93F826D106Q26772015-6161E3DF-EA5D-4E71-B75A-37B86EEA16ADQ26772277-0B5F4675-EF3F-4FBD-825F-866C92CE280CQ26773302-C4A5C2F3-0644-42F5-9A48-01653C41658EQ26775546-17B1F1D9-AB5D-43C1-AF15-81AE16D1609EQ26775598-5D01AF2F-B021-4CEF-B687-F45B0371E503Q26776394-0A22170C-E611-4077-BE08-E31F787E1988Q26778769-304D2EAB-B8B6-40D2-B842-D3DA605E01F5Q26781931-B190C3AD-9110-434A-A10A-8A1C4B9261FAQ26782222-C7760B81-2DC4-4F04-97DE-4A0D0DFFBE76Q26786366-166DC773-A434-4FA8-815B-5DAB53AE27C5Q26795510-6DC03343-05D0-4B51-973D-8B33BC927572Q26796309-77DC46E2-C991-4D21-ABBB-4170CFD03D72Q26822793-AA17B1B0-657B-4859-9D20-BA5CC040A1C2Q26824310-BC0F6665-1F04-411A-9E7E-10FBAB470C14Q26824536-3DF2414C-1D19-4868-BF18-1CC1E1849061Q26825316-8C3EBB13-F1E1-489D-8D37-2130A53AE06DQ26829997-6233A746-8668-4792-9743-8F007E5CFF17Q26850001-216AD0A7-72C0-45CB-9A85-4C2AD9F4A173Q26852704-E6A452A2-F7B1-44DB-9C9B-0E436FEA8CF1Q26866803-1C28862E-D91F-4004-B6DD-3446B9339B09
P2860
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@ast
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@en
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@nl
type
label
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@ast
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@en
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@nl
prefLabel
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@ast
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@en
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@nl
P2093
P2860
P50
P3181
P356
P1476
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
@en
P2093
Andrew K Joe
Anna C Pavlick
Donald Lawrence
H Jeffrey Lawrence
Jeffrey A Sosman
Jeffrey S Weber
Karl D Lewis
Keith B Nolop
P2860
P304
P3181
P356
10.1056/NEJMOA1112302
P407
P5008
P577
2012-02-23T00:00:00Z